Cooper Companies Inc (NYSE:COO) – Equities researchers at KeyCorp dropped their Q3 2018 earnings estimates for Cooper Companies in a note issued to investors on Thursday. KeyCorp analyst M. Mishan now anticipates that the medical device company will post earnings per share of $2.97 for the quarter, down from their prior estimate of $3.02. KeyCorp has a “Hold” rating on the stock.
A number of other analysts also recently issued reports on COO. Zacks Investment Research raised shares of Cooper Companies from a “hold” rating to a “buy” rating and set a $265.00 target price for the company in a research report on Tuesday, October 10th. BMO Capital Markets reaffirmed a “buy” rating and issued a $272.00 price objective on shares of Cooper Companies in a research report on Friday, October 13th. Robert W. Baird set a $273.00 price objective on shares of Cooper Companies and gave the company a “buy” rating in a research report on Monday, October 16th. Raymond James Financial reaffirmed a “buy” rating and issued a $265.00 price objective on shares of Cooper Companies in a research report on Monday, December 4th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and issued a $265.00 price objective (down previously from $275.00) on shares of Cooper Companies in a research report on Friday, December 8th. Seven equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Cooper Companies has a consensus rating of “Buy” and an average price target of $259.70.
Cooper Companies (NYSE COO) traded down $0.51 on Monday, reaching $230.48. 29,550 shares of the company were exchanged, compared to its average volume of 487,803. The firm has a market cap of $11,812.43, a P/E ratio of 30.72, a PEG ratio of 1.95 and a beta of 0.57. Cooper Companies has a 12-month low of $186.83 and a 12-month high of $256.39. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.26 and a current ratio of 2.41.
Cooper Companies (NYSE:COO) last posted its earnings results on Thursday, December 7th. The medical device company reported $2.65 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.64 by $0.01. The firm had revenue of $561.50 million during the quarter, compared to the consensus estimate of $558.86 million. Cooper Companies had a net margin of 17.43% and a return on equity of 16.02%. The company’s revenue was up 8.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.28 EPS.
Several institutional investors and hedge funds have recently modified their holdings of COO. Koch Industries Inc. acquired a new position in shares of Cooper Companies during the second quarter valued at $312,000. American Century Companies Inc. increased its holdings in shares of Cooper Companies by 471.0% during the third quarter. American Century Companies Inc. now owns 316,233 shares of the medical device company’s stock valued at $74,982,000 after purchasing an additional 260,847 shares during the period. Westfield Capital Management Co. LP increased its holdings in shares of Cooper Companies by 47.8% during the third quarter. Westfield Capital Management Co. LP now owns 636,882 shares of the medical device company’s stock valued at $151,011,000 after purchasing an additional 206,003 shares during the period. Legal & General Group Plc increased its holdings in shares of Cooper Companies by 162.8% during the third quarter. Legal & General Group Plc now owns 254,120 shares of the medical device company’s stock valued at $60,232,000 after purchasing an additional 157,416 shares during the period. Finally, Assenagon Asset Management S.A. acquired a new position in Cooper Companies during the third quarter worth about $18,948,000. 96.35% of the stock is currently owned by institutional investors.
In other news, Director Gary S. Petersmeyer sold 785 shares of the firm’s stock in a transaction on Friday, December 15th. The stock was sold at an average price of $229.06, for a total transaction of $179,812.10. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director A Thomas Bender sold 9,150 shares of the firm’s stock in a transaction on Monday, December 18th. The shares were sold at an average price of $229.17, for a total value of $2,096,905.50. Following the transaction, the director now directly owns 11,205 shares in the company, valued at $2,567,849.85. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 54,385 shares of company stock valued at $12,289,463. Company insiders own 1.60% of the company’s stock.
The firm also recently announced a semiannual dividend, which will be paid on Friday, February 9th. Stockholders of record on Tuesday, January 23rd will be paid a dividend of $0.03 per share. This represents a dividend yield of 0.03%. The ex-dividend date is Monday, January 22nd. Cooper Companies’s dividend payout ratio (DPR) is currently 0.80%.
ILLEGAL ACTIVITY WARNING: This news story was first posted by Stock Observer and is the property of of Stock Observer. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The legal version of this news story can be read at https://www.thestockobserver.com/2018/02/06/q3-2018-eps-estimates-for-cooper-companies-inc-lowered-by-analyst-coo.html.
Cooper Companies Company Profile
The Cooper Companies, Inc is a global medical device company. The Company operates through two business units: CooperVision, Inc and CooperSurgical, Inc CooperVision offers soft contact lenses for the vision correction market. CooperVision develops, manufactures and markets a range of single-use, two-week and monthly contact lenses.
Receive News & Ratings for Cooper Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cooper Companies and related companies with MarketBeat.com's FREE daily email newsletter.